Is diabetes curable? What really lies behind the 2026 breakthroughs

Key takeaway
No, diabetes cannot be cured today. The Federal Office of Public Health describes type 1 as incurable to date (paraphrased from its German, French and Italian pages; there is no English version). Behind the breakthrough headlines are studies at an early stage. The ETH Zurich implant was tested in mice (Science, 22 October 2026), the stem-cell therapy from Beijing in a single person (phase I, Cell 2024), zimislecel in 14 people: after one year, 10 of 12 no longer needed insulin, all of them on anti-rejection drugs (phase 1–2, NEJM 2025). None of them is authorised in Switzerland (Swissmedic, as of 31 October 2026). Around half a million people in Switzerland have diabetes.
This page puts studies and approvals in context. It does not replace medical advice.

Every so often a laboratory announces a “breakthrough” against diabetes. Anyone affected reads each of these headlines with hope. Here is what the studies themselves say: who was tested, at which stage, when they were published, and what of it is authorised in Switzerland.

WhatsApp
Mice
ETH implant
tested in animals, Science 22 October 2026
1
person
Stem-cell therapy, Beijing, phase I (Cell 2024)
10 of 12
insulin-free after 1 year
Zimislecel, phase 1–2, on immunosuppression (NEJM 2025)
6.2%
of the population aged 15+
report diabetes, 2022; 2017: 4.8% (Obsan)

🔬 Breakthrough check: every headline with its stage, participants and approval

Of the three announcements most widely shared as a “breakthrough”, none has moved beyond the early trial phase. The largest was tested in 14 people. What is authorised in Switzerland, by contrast, are medicines that rarely make headlines.

The ConvivaPlus Breakthrough Check lists every announcement with its primary source: stage (laboratory and animal, phase I to III, authorised), number of people tested, date of publication and approval status at Swissmedic. Every row carries the date it was checked. New announcements are added as soon as a publication exists.

ApproachTypeStageTested inPublished / authorisedSwissmedicChecked on
Implant breaks down blood sugar electrically (ETH Zurich, “ECHO”)Type 2Animal study (mice)0 humans22/10/2026not authorised16/11/2026
Insulin-producing cells from the patient’s own reprogrammed stem cells (Beijing)Type 1Phase I1 person25/09/2024not authorised16/11/2026
Islets from donor stem cells (zimislecel, Vertex)Type 1Phase 1–214 people20/06/2025not authorised16/11/2026
Ozempic: semaglutide (injection)Type 2authorisedapproval studies02/07/2018authorised16/11/2026
Mounjaro: tirzepatide (injection)Type 2authorisedapproval studies02/11/2022authorised16/11/2026
Rybelsus N: semaglutide (tablet)Type 2authorisedapproval studies28/11/2025authorised16/11/2026

🐭 ETH diabetes implant: a breakthrough in mice

The latest Swiss “breakthrough” has not yet reached a single human. The implant from ETH Zurich’s Department of Biosystems Science and Engineering in Basel brought blood sugar in mice with type 2 diabetes down to normal levels within 1 hour and regulated it for 6 weeks without hypoglycaemia (Science, 22 October 2026).

The device uses electricity to convert excess sugar in the blood into gluconate, which the kidneys excrete. Coupled to a standard glucose sensor, it switches itself on. The mice also lost weight. The researchers call it ECHO. The publication does not describe any trials in humans.

🇨🇳 Diabetes cure from China: one person, phase I

Behind the widely shared “cure from China” is a single person with type 1 diabetes. The paper in Cell (25 September 2024) reports the one-year results as the first analysis of a phase I study (ChiCTR2300072200).

Hongkui Deng’s team chemically reprogrammed the person’s cells into stem cells, grew insulin-producing islets from them and placed them beneath the abdominal anterior rectus sheath. From day 75, the person no longer needed injected insulin. Time in the target blood-sugar range rose from 43.18% to 96.21% by month four. The authors themselves write that further clinical studies “are warranted”.

🧬 Stem cells against type 1: 10 of 12 insulin-free, at a price

The largest of these studies shows the strongest result and the highest price: 10 of the 12 people who received the full dose of zimislecel were no longer injecting insulin after one year (83%). But all participants were given drugs that suppress the immune system.

Zimislecel consists of islet cells grown from donor stem cells and infused into the portal vein of the liver. The study (phase 1–2, 14 participants, NEJM 20 June 2025) was funded by Vertex. 2 participants died during the study: one of cryptococcal meningitis, a fungal infection of the brain lining, and one of progressive dementia with pre-existing impairment. The authors call it a “small, short-term study”.

💉 Approved medicines in Switzerland: what already exists for type 2

The biggest change of recent years came without a “breakthrough” headline: medicines such as semaglutide and tirzepatide are authorised in Switzerland for type 2 diabetes, the first since 2 July 2018.

MedicineActive ingredientFirst authorised by Swissmedic
Ozempicsemaglutide (injection)02/07/2018
Mounjarotirzepatide (injection)02/11/2022
Rybelsus Nsemaglutide (tablet)28/11/2025

The table shows the first authorisation according to the official Swissmedic list (as of 31 October 2026). Whether a medicine is right for someone is for their doctor to decide, not a table. Zimislecel and the other trial therapies are not on the list.

Higher deductible or lower? How long you still have to cancel your health insurance for 2027Cancelling health insurance: 30 November deadline, template and choice of deductibleSame active substance as Ozempic, but 3 years at most: when does insurance pay for Wegovy?Wegovy Switzerland insurance 2026: stopped even if it works, with the insurance stopwatch

📈 Diabetes in Switzerland: statistics up almost a third in five years

In 2022, 6.2% of the population aged 15 and over said they had diabetes or were taking medication for it. Five years earlier it was 4.8% (Obsan, Swiss Health Survey).

Group (Obsan, Swiss Health Survey)20172022
Population aged 15+4.8%6.2%
Women4.5%5.6%
Men5.1%6.9%

Diabetes does not affect everyone equally: without post-compulsory education the share is 12.7%, with a tertiary degree 4.8%. Without an apprenticeship or upper secondary school it is around 2.6 times as high (2022; upper secondary: 7.5%).

According to Obsan, most people with diabetes take medication other than insulin, around a fifth inject insulin and about a third take no medication. The survey does not reliably separate type 1 from type 2. The Federal Office of Public Health estimates the number of people with diabetes at around half a million, about 10% with type 1 and around 90% with type 2.

Same basic insurance, a different premium in every canton: where do you pay least?Switching health insurer: premiums and deductibles by canton

🌍 Diabetes worldwide: 589 million, not 425

The figure of “425 million people with diabetes” that still circulates is the 2017 figure. In its 2025 Atlas, the International Diabetes Federation counts 589 million adults, 164 million more.

According to the IDF, 252 million of them do not know they have diabetes. For 2050, the Federation expects 853 million. The count covers adults aged 20 to 79.

Health costs and premiums: what does the Federal Council say when asked whether foreigners drive them up?Health insurance premiums and foreigners: the Federal Council’s reply word for word (in German)

🛡️ Preventing type 2: what the FOPH says

Fact check

According to the FOPH, type 1 cannot be influenced, as it is an autoimmune disease. With type 2, heredity plays a part, but the FOPH names excess weight and a positive energy balance as decisive, and says these risk factors can be countered with enough physical activity and a balanced diet (paraphrased; the FOPH page exists only in German, French and Italian).

This page puts studies and approvals in context. It does not replace medical advice.

❓ Frequently asked questions

Diabetes cures and breakthroughs: the most common questions, answered with the studies themselves, Swissmedic and the FOPH.

Sourced sentence by sentence · checked against the sources · researched with the help of artificial intelligence · How we work ›

ConvivaPlus EditorialEditorial ›

Found an error or have feedback? Let us know or write to us directly.